Concert Pharmaceuticals Inc. (CNCE)

10.76
NASDAQ : Health Technology
Prev Close 11.02
Day Low/High 10.69 / 11.16
52 Wk Low/High 9.21 / 20.21
Avg Volume 320.60K
Exchange NASDAQ
Shares Outstanding 23.80M
Market Cap 262.23M
EPS -2.40
P/E Ratio N/A
Div & Yield N.A. (N.A)
Concert Pharmaceuticals To Participate At Upcoming Investor Conferences

Concert Pharmaceuticals To Participate At Upcoming Investor Conferences

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will participate at the following upcoming investor conferences: The Stifel 2018 Healthcare Conference on November 14, 2018, at 2:00 p.

Concert Pharmaceuticals Presents Preclinical Data On CTP-692, A Novel Drug Candidate For Schizophrenia, Supporting Potential To Improve Safety Profile Of D-Serine

Concert Pharmaceuticals Presents Preclinical Data On CTP-692, A Novel Drug Candidate For Schizophrenia, Supporting Potential To Improve Safety Profile Of D-Serine

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today presented preclinical results that support the potential of CTP-692, the Company's novel drug candidate for schizophrenia, to improve the safety profile of D-serine.

Concert Pharmaceuticals Reports Third Quarter 2018 Financial Results And Provides Company Update

Concert Pharmaceuticals Reports Third Quarter 2018 Financial Results And Provides Company Update

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the third quarter of 2018.

Concert Pharmaceuticals To Report Third Quarter 2018 Financial Results On November 1, 2018

Concert Pharmaceuticals To Report Third Quarter 2018 Financial Results On November 1, 2018

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its third quarter 2018 financial results on Thursday, November 1, 2018, before the U.

Concert Pharmaceuticals Amends Protocol Of Phase 2a Trial To Evaluate 12 Mg Twice-Daily Dose Cohort Of CTP-543 For The Treatment Of Alopecia Areata

Concert Pharmaceuticals Amends Protocol Of Phase 2a Trial To Evaluate 12 Mg Twice-Daily Dose Cohort Of CTP-543 For The Treatment Of Alopecia Areata

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will include an additional cohort of patients in the Phase 2a trial evaluating CTP-543.

Concert Pharmaceuticals Enters Oversold Territory (CNCE)

Concert Pharmaceuticals Enters Oversold Territory (CNCE)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Concert Pharmaceuticals To Present At Upcoming Investor Conferences

Concert Pharmaceuticals To Present At Upcoming Investor Conferences

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will present a corporate overview at the following upcoming investor conferences: The Wells Fargo Securities 2018 Healthcare Conference on September 5, 2018 at 10:15 a.

Concert Pharmaceuticals Reports Second Quarter 2018 Financial Results And Provides Company Update

Concert Pharmaceuticals Reports Second Quarter 2018 Financial Results And Provides Company Update

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the second quarter of 2018.

Concert Pharmaceuticals Is Now Oversold (CNCE)

Concert Pharmaceuticals Is Now Oversold (CNCE)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Concert Pharmaceuticals To Report Second Quarter 2018 Financial Results On August 2, 2018

Concert Pharmaceuticals To Report Second Quarter 2018 Financial Results On August 2, 2018

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its second quarter 2018 financial results on Thursday, August 2, 2018, before the U.

Relative Strength Alert For Concert Pharmaceuticals

Relative Strength Alert For Concert Pharmaceuticals

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Concert Pharmaceuticals Reports First Quarter 2018 Financial Results

Concert Pharmaceuticals Reports First Quarter 2018 Financial Results

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the first quarter of 2018.

Concert Pharmaceuticals To Report First Quarter 2018 Financial Results On May 3, 2018, And Present At Upcoming Investor Conferences

Concert Pharmaceuticals To Report First Quarter 2018 Financial Results On May 3, 2018, And Present At Upcoming Investor Conferences

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its first quarter 2018 financial results on Thursday, May 3, 2018, before the U.

Concert Pharmaceuticals Completes Enrollment In Phase 2a Trial Of CTP-543 In Alopecia Areata

Concert Pharmaceuticals Completes Enrollment In Phase 2a Trial Of CTP-543 In Alopecia Areata

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has completed patient enrollment of its Phase 2a trial evaluating CTP-543 for the treatment of moderate-to-severe alopecia areata.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: PNNT, PTN, VTSI Downgrades: BRN, CNCE, CRWS, DFIN, FF, HDSN, NRT, PFLT, WPM Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Concert Pharmaceuticals Present At Upcoming Investor Conferences

Concert Pharmaceuticals Present At Upcoming Investor Conferences

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will present a corporate overview at the following upcoming investor conferences: The Cowen 38th Annual Healthcare Conference on...

First Week of CNCE March 16th Options Trading

First Week of CNCE March 16th Options Trading

Investors in Concert Pharmaceuticals Inc saw new options begin trading this week, for the March 16th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the CNCE options chain for the new March 16th contracts and identified one put and one call contract of particular interest.

Concert Pharmaceuticals Reports Year Ended 2017 Financial Results

Concert Pharmaceuticals Reports Year Ended 2017 Financial Results

Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) today reported financial results for the year ended December 31, 2017, as well as provided an update on its product pipeline and corporate activities.

Concert Pharmaceuticals Announces Advancement Of Novel Drug Candidate In Schizophrenia

Concert Pharmaceuticals Announces Advancement Of Novel Drug Candidate In Schizophrenia

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced the next development candidate in its product pipeline with the selection of CTP-692, a novel drug for adjunctive treatment of schizophrenia, a...

Concert Pharmaceuticals To Report Full Year 2017 Results On March 1, 2018

Concert Pharmaceuticals To Report Full Year 2017 Results On March 1, 2018

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its financial results for the year ended December 31, 2017, on Thursday, March 1, 2018, before the U.

Concert Pharmaceuticals Announces Initiation Of Enrollment In Second Cohort Of CTP-543 Phase 2a Trial For Alopecia Areata

Concert Pharmaceuticals Announces Initiation Of Enrollment In Second Cohort Of CTP-543 Phase 2a Trial For Alopecia Areata

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has initiated enrollment of the second cohort of its Phase 2a clinical trial evaluating CTP-543.

Commit To Purchase Concert Pharmaceuticals At $17.50, Earn 23.6% Annualized Using Options

Commit To Purchase Concert Pharmaceuticals At $17.50, Earn 23.6% Annualized Using Options

Investors eyeing a purchase of Concert Pharmaceuticals Inc stock, but cautious about paying the going market price of $19.90/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the July put at the $17.50 strike, which has a bid at the time of this writing of $1.90.

FDA Grants Fast Track Designation To Concert Pharmaceuticals' CTP-543 For The Treatment Of Alopecia Areata

FDA Grants Fast Track Designation To Concert Pharmaceuticals' CTP-543 For The Treatment Of Alopecia Areata

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that the U.

Concert Pharmaceuticals Announces Patent Trial And Appeal Board Did Not Institute PGR Proceeding

Concert Pharmaceuticals Announces Patent Trial And Appeal Board Did Not Institute PGR Proceeding

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that the Patent Trial and Appeal Board (PTAB) of the U.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ATNI, CNCE, JTPY, KS Downgrades: DGICB, HELE, RLGY Initiations: GDP, POLA, SNES Read on to get TheStreet Quant Ratings' detailed report:

Concert Pharmaceuticals Announces The Appointment Of Marc Becker As Chief Financial Officer

Concert Pharmaceuticals Announces The Appointment Of Marc Becker As Chief Financial Officer

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced the appointment of Marc Becker as Chief Financial Officer, effective January 4, 2018.

Concert Pharmaceuticals To Be Added To NASDAQ Biotechnology Index

Concert Pharmaceuticals To Be Added To NASDAQ Biotechnology Index

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has been selected for addition to the NASDAQ Biotechnology Index (NASDAQ: NBI) effective prior to the market open on Monday, December 18, 2017.

CNCE Crosses Above Average Analyst Target

CNCE Crosses Above Average Analyst Target

In recent trading, shares of Concert Pharmaceuticals Inc have crossed above the average analyst 12-month target price of $24.67, changing hands for $24.86/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ABAX, ATKR, AUTO, BIO.B, BWINB, CNCE, EGY, NWS, RADA, RFP, SBNY, SORL, WDAY, XOMA Downgrades: ATRC, CCR, GPRK, GWRE, HCAP, KODK, SNPS Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Concert Pharmaceuticals Reports Third Quarter 2017 Financial Results And Provides Company Update

Concert Pharmaceuticals Reports Third Quarter 2017 Financial Results And Provides Company Update

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the third quarter of 2017.

TheStreet Quant Rating: D (Sell)